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ABSTRACT 
 
 
Study Objectives 
Obstructive sleep apnea (OSA) has been linked to a large number of 
cardiovascular diseases.  However, the link between OSA and venous 
thromboembolic events (VTE) remains unclear.  We sought to study 
the possible association between VTE and OSA.  
Design 
Retrospective study (August 1999 - April 2009). 
Setting 
University Tertiary Center. 
Patients 
We retrospectively collected data on patients with objectively 
confirmed VTE.  Primary outcome was prevalence of OSA defined as an 
apnea-hypopnea index (AHI) > 5.  Data on demographics and co-
morbidities were recorded as well as body-mass index was calculated. 
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Measurements and Results 
840 patients were identified as having VTE and analyzed for 
presence/absence of co-morbidities.  Of 840 patients, 130 (15.5%) 
were also diagnosed with OSA.  Compared to the control group (no 
OSA), those who had OSA were more obese (83.8% versus 43.8%) 
and had statistically higher prevalence of diabetes, coronary artery 
disease (CAD), and congestive heart failure (CHF).  OSA patients had 
higher prevalence of pulmonary embolism but similar prevalence of 
deep vein thrombosis. 
 
Conclusions 
In this VTE cohort, the prevalence of OSA (15.5%) appears to 
be higher than that of the general population (2-10%).  Our 
data suggest that patients with both OSA and VTE are more 
likely to be obese with diagnoses of CAD, CHF, and diabetes 
than their counterparts with VTE alone.  OSA patients had 
higher prevalence of pulmonary embolism compared to 
controls.  Although OSA has been clearly linked to arterial 
thrombosis, this study also suggests a link between OSA and 
venous thrombotic disorders. 
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ABBREVIATIONS 
 
 
VTE – Venous Thromboembolic Event 
PE – Pulmonary Embolism 
DVT – Deep Vein Thrombosis 
OSA – Obstructive Sleep Apnea 
CHF – Congestive Heart Failure 
CVA – Cerebrovascular Accident 
BMI – Body Mass Index 
CAD – Coronary Artery Disease 
ROC – Receiver Operating Characteristics 
AUC – Area Under the Curve 
AHI – Apnea-Hypopnea Index 
CHADS2 - clinical prediction tool for predicting risk of stroke 
in patients with atrial fibrillation 
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INTRODUCTION 
 
Venous thromboembolism (VTE), defined as deep vein 
thrombosis (DVT) and/or pulmonary embolism (PE), is a common and 
highly prevalent disease which affects an estimated 350,000 to 
600,000 people in the United States every year and claims the lives of 
at least 100,000 [1].  Multiple risk factors increase the risk for DVT, 
including trauma, surgery, cancer, hormone therapy and others [1].  
Obesity is one of the several conditions related to the development of 
VTE.  Additionally, obesity is a known risk factor for Obstructive Sleep 
Apnea (OSA) and affects the disease severity [2]. The prevalence of 
OSA ranges between 2-10% of the general adult population in the 
United States [3], however this is likely underestimated due to under 
diagnosis of the disease [4].   
 
OSA has been linked to many of cardiovascular diseases, 
including hypertension, ischemic heart disease, congestive heart 
failure (CHF), cerebrovascular accidents (CVA), pulmonary 
hypertension, cardiac arrhythmias, end-stage renal disease and overall 
cardiovascular mortality [5-7].  Conversely, the link of OSA to VTE, 
another cardiovascular disease, is not well established.  At least two 
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published reports have suggested a relationship between OSA and 
VTE.  However, both studies suffered from low sample size and design 
limitations [8-9].  Due to the unclear association between OSA and 
VTE, we sought to study the potential relationship and estimate the 
prevalence of OSA among patients with VTE. 
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BACKGROUND 
 
Venous Thromboembolism 
 
Venous thromboembolism (VTE) is a common and highly 
prevalent disease with high morbidity and mortality.  VTE affects an 
estimated 350,000 to 600,000 people in the United States every year 
and claims the lives of at least 100,000 [1].  VTE encompasses both 
deep vein thrombosis (DVT) and pulmonary embolism (PE).  DVT 
refers to a blood clot in one of the “deep” or large veins of the body.  
DVTs usually begin in the lower leg or calf or distal upper extremity, 
then propagate proximally [10].  PE occurs when a portion of the 
proximal clot in one of the large veins breaks off and travels through 
the heart into the pulmonary arteries.  PE occurs in over one-third of 
patients with DVTs and is a life-threatening complication [10].   
 
Over 50 percent of DVTs are asymptomatic [11].  However, 
DVTs can lead to pain, swelling, warmth, tenderness, discoloration, 
and/or erythema of the area [1].  PE symptoms include tachypnea, 
tachycardia, diaphoresis, pleuritic chest pain and/or hemoptysis [1].  
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Approximately 15 percent of PEs are fatal with 10 percent being 
rapidly fatal [10].  Death due to PE results from right ventricular 
failure [12]. 
 
While the most dreaded complication of a DVT is a PE, DVTs can 
also lead to additional complications.  Approximately 30 percent of 
patients that develop a DVT deal with subsequent problems 
encompassed by the term post-phlebitic syndrome.  These include 
chronic leg swelling and pain, skin breakdown and ulceration, chronic 
thromboembolic disease, and pulmonary hypertension [13].  Further, 
after the first episode of DVT, a patient remains at higher risk for 
additional DVTs in the future [13].  Of those that deal with a first 
episode of DVT, 30 percent will suffer from another DVT in the 
following 10 years, with the highest risk in the first 2 years [14].  
Multiple risk factors increase the risk for DVT, including obesity, 
trauma, surgery, cancer, hormone therapy, cancer and others [1].    
Obstructive Sleep Apnea (OSA) shares many risk factors with VTE, 
most notably, obesity.  Obesity also affects OSA disease severity [2, 
15]. 
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Obstructive Sleep Apnea 
 
OSA is a disorder in which repetitive interruptions of ventilation 
occur during sleep by obstruction of the pharyngeal airway due to loss 
of muscle tone [16].  The disease is characterized by signs of 
disturbed sleep,  sleepiness or fatigue and abnormal sleep breathing 
patterns [16].  OSA was first believed to be described by Charles 
Dickens in 1837 when he coined the term “Pickwickian.”  This term 
was then adapted and used by Sir William Osler in the early 20th 
century and by Dr. Burwell in the 1950s.  In 1965, Gastault et al noted 
that patients with this syndrome had apneic events during sleep.  In 
1969, Kuhlo et al noted that patients with this syndrome were 
successfully treated with tracheostomy.  In 1978, Remmers et al 
studied the mechanisms by which the upper airway collapsed during 
sleep, which began the term “obstructive sleep apnea.”   Finally in 
1981, Sullivan et al published a paper on successful treatment of OSA 
with continuous positive airway pressure  [17-18]. 
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OSA is estimated to affect at least 2-10% of the general adult 
population in the United States and continues to increase in prevalence 
due to the obesity epidemic [3].  Obesity is thought to contribute to 
OSA by increasing the volume of pharyngeal soft tissue and reducing 
the airway diameter, thus increasing likelihood of airway collapse.    
Normally, reflex-driven muscle activation is required to maintain 
patency in the upper airway in OSA prone individuals.  This reflex is 
compromised during sleep leading to apneic or hypopnic events [15].  
Furthermore, there is evidence that OSA is under-diagnosed.  For 
example, in a subset of surgical patients, less than 20% of the 
patients with clinically significant OSA had previously been diagnosed 
with the condition [4].  Other studies claim that >85% of patients with 
OSA have never been diagnosed and would benefit from treatment 
[19]. 
 
OSA is defined by an Apnea-Hypopnea Index (AHI) >5 in a 
symptomatic patient [16].  OSA is diagnosed after an overnight sleep 
study where the AHI is determined, with apnea defined as a >10 sec 
pause in breathing and hypopnea defined as decreases in breathing 
that lead to a fall in oxygen saturation or arousal [15].  The total 
number apnic and hypopnic events are totaled and divided over the 
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hours of sleep to yield the AHI index which is used to categorize 
severity of OSA. 
 
OSA results in secondary disease by a number of mechanisms 
including increased cytokine levels, hypoxia and hypercarbia.  In 
healthy subjects, sleep deprivation alone has been shown to increase 
levels of C-reactive peptide, interleukin-6 and tumor necrosis factor-
alpha [20-23].  OSA leads to subsequent hypoxia and hypercarbia, 
which activates the sympathetic nervous system and diminishes 
cardiovascular variability [15].  Oxygen saturations have been 
documented as low as 60% during these events and this disrupts the 
normal "autonomic and hemodynamic responses to sleep" [24].   
 
OSA also leads to the release of vasoactive substances 
(endothelin and aldosterone), inflammatory and oxidative stress 
markers (plasma cytokines, adhesion molecules, C-reactive protein, 
superoxide, nitrotyrosine) and leads to endothelial dysfunction 
(resistance to vessel relaxation with acetylcholine), insulin resistance, 
intrathoracic pressure changes, and thrombosis (increased platelet 
activation and  fibrinogen) [15, 25-26].  Furthermore, reactive oxygen 
species are more abundant with OSA (specifically superoxide) and 
have been shown to destabilize the endothelial nitric oxide synthase 
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messenger RNA and decrease nitric oxide production by over 60% [26-
29].  
 
Endothelial damage and oxidative stress markers have been 
shown to resolve after initiation of treatment for OSA (continuous 
positive airway pressure), providing further proof that OSA is directly 
related to these findings [26].  In addition, prolonged hypoxia has 
been shown to induce the transcription factor hypoxia-inducible factor-
1 that subsequently leads to erythropoietin and vascular endothelial 
growth factor production [30-31].  In sum, OSA seems to contribute to 
a microvascular inflammatory state, similar to that of hypertension 
and diabetes mellitus. 
 
Several factors influence the development of OSA.  Age and 
obesity are noted to increase risk of OSA and the severity of disease 
can be linked with BMI [2, 15].  Race seems to play a role, as the risk 
for blacks exceeds that for whites [32].  Gender has also been shown 
to affect the prevalence of OSA.  Men appear to have 2-3 times the 
risk of developing OSA as compared to females [33].  Pre-menopausal 
women or post-menopausal women on hormone replacement therapy 
have a significantly lower risk in the development of OSA as compared 
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to post-menopausal women not on hormone replacement therapy 
[34].   
 
Due to the increasing prevalence and under-diagnosis of OSA, 
the co-morbidities associated with this disease continue to expand.  
OSA has been linked to a large number of cardiovascular diseases, 
including hypertension (30-83%) [35-36], ischemic heart disease (30-
58%) [37-38], congestive heart failure (CHF) (12-53%) [39-41], 
cerebrovascular accidents (CVA) (43-91%) [42-44], pulmonary 
hypertension, cardiac arrhythmias, end-stage renal disease and overall 
cardiovascular mortality [5-7].  OSA has also been linked to type II 
diabetes [45].  OSA patients that are not treated for their disease 
clearly have increased mortality from cardiovascular events [46].   
 
The link of OSA to VTE events, another cardiovascular disease, is 
not well established.  At least two published reports have suggested a 
potential relationship between OSA and VTE.  However, both reports 
suffered from low sample size and design limitations [8-9].  
Nevertheless, many studies have investigated the link between OSA 
and a thrombotic phenotype. 
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Obstructive Sleep Apnea and Thrombosis 
 
Multiple studies have confirmed that OSA induces an 
inflammatory phenotype and a prothrombotic state [47-48].  Patients 
with OSA have increases in plasma cytokines, adhesion molecules, 
leukocyte activation and TNF-alpha [15].  OSA also leads to alterations 
in the levels of vasoactive substances, including  increases in 
endothelin [49], and  aldosterone [50], and decreases in nitric oxide 
[51].  Recent studies have established the association between OSA, 
endothelial dysfunction/apoptosis [26, 52-54], and elevated C-reactive 
peptide levels [55].  In patients with OSA, microvascular endothelial 
function (tested by relaxation to acetylcholine) has been shown to be 
impaired.  In addition, this impairment is reversed with proper OSA 
treatment [56].  Regarding hypercoagulability, von Kanel et al. has 
shown that patients with OSA have elevations in prothrombotic 
factors.  These include increased plasma fibrinogen, reductions in 
fibrinolytic capacity, activation of clotting factors, and heightened 
platelet activity [47-48]. 
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Since the late 1800s from Dr. Virchow’s epidemiological studies, 
Virchow’s triad has been studied as the foundation for thrombosis and 
VTEs.  Virchow’s triad includes alterations in blood 
(hypercoagulability), alterations in vessels (endothelial damage), and 
alterations in blood flow (stasis).  OSA has been shown to induce an 
inflammatory phenotype with endothelial damage and a 
hypercoagulable state, consistent with Virchow’s triad.  With the 
addition of stasis, which is found in many medical conditions (including 
hospitalization itself), there is a large increase in the risk for VTE.  
Although OSA has been linked with arterial thrombosis, the goal of this 
study is to link OSA with the venous thrombotic disorders. 
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Venous Thromboembolism and  
Obstructive Sleep Apnea 
 
In summary, VTE is a disease that carries high morbidity and 
mortality.  The list of risk factors for the development of VTE continues 
to expand.  OSA is one such disease that appears to be a logical fit for 
inclusion as a risk factor for VTE.  OSA has been linked to multiple 
cardiovascular diseases, diseases of arterial thrombosis, and a 
prothrombotic phenotype.  OSA, by itself or its downstream mediators, 
affects all three corners of Virchow’s triad.  A relationship between 
OSA and VTE seems a logical conclusion, but the link remains unclear.   
 
The following study is designed to examine if patients with VTE 
have a higher prevalence of OSA than the general population.  We 
hypothesize that OSA leads to a prothrombotic phenotype that 
increases the risk of developing VTEs.  In the same line, we 
hypothesize that patients that have developed previous VTEs will have 
a higher percentage of patients (prevalence) with OSA.  As OSA and 
VTE carry that same risk factor of obesity, we hope to be able to 
discern if VTE and OSA are linked independent of adiposity.  
Furthermore, due to the concurrence of OSA and multiple other 
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medical conditions (diabetes, CAD, CHF and stroke), we expect that 
patients with both VTE and OSA will have a higher prevalence of these 
medical conditions. 
 
Being able to discern a patient population that carries a higher 
risk of VTE would be invaluable in prevention and treatment of this 
disorder.  As the CHADS score (and other risk stratifying scoring 
systems) is currently used to predict the risk of stroke in patients with 
atrial fibrillation, the existence of OSA could be added as a factor in 
predicting the risk of VTE in patients.  Currently the prevention of VTE 
applies mostly to hospitalized patients, however, some clinicians are 
even questioning if VTE prophylaxis should be applied to selected 
patients in the outpatient setting.  Nevertheless, discerning if OSA 
induces a pro-VTE phenotype would alter the current 
recommendations for prophylaxis.  Regarding treatment, 
recommendations for the length of anticoagulation are variable.  If 
OSA is found to be a risk factor for VTE, a longer duration of 
anticoagulation might benefit patients with OSA.   
 
The primary hypothesis of this study is that patients with VTE 
have a higher prevalence of OSA than the general population.  If this 
hypothesis holds true, clinicians may want to question their patients 
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with VTE for the risk factors of OSA and consider a polysomnogram.  
As mentioned above, OSA is a treatable disease and treatment alters 
the disease outcome.  This study has the potential to alter clinical 
practice and help to draw attention to the association of VTE and OSA. 
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Methods 
 
Design and Setting 
 
A retrospective study was conducted at the University of Missouri 
Hospitals and Clinics from August 1999 to April 2009.  This center is a 
tertiary university hospital and is equipped with 8 beds for 
polysomnography. The Institutional Review Board from the University 
of Missouri approved the study under the exempt category.  The study 
was registered at clinicaltrials.gov (NCT01051297). 
 
Patients 
 
All adult patients (>18 years of age) with ICD-9 coding indicative 
of VTE were included.   The initial search contained all of the following 
ICD-9 codes: 415.11, 415.12, 415.19, 453.4, 453.9, 453.41, 453.42, 
671.33, 671.44.  The study investigators then reviewed the charts 
extensively to verify the clinical diagnosis of VTE.  The study 
investigators did not independently adjudicate any of the clinical 
findings.  VTE was defined as the objective diagnosis of pulmonary 
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embolism (PE) or deep vein thrombosis (DVT).  VTE was confirmed by 
extremity venous-doppler ultrasonography (abnormal compression 
ultrasound), venography, spiral CT of the chest (a new intraluminal 
filling defect in segmental or more proximal branches on spiral CT 
scan), high probability ventilation-perfusion VQ scan (a new perfusion 
defect of at least 75% of a segment with a local normal ventilation 
result), or pulmonary angiography (a new intraluminal filling defect, or 
an extension of an existing defect, or a new sudden cutoff of vessels 
more than 2.5 mm in diameter on the pulmonary angiogram).  Only 
confirmed VTE patients (as listed in past medical history or per 
available records of radiographic testing) were included in the study.   
Patients without objective confirmation of VTE were excluded.  If the 
status of OSA or height and weight could not be ascertained, then such 
patients were also excluded. 
 
Measurements 
 
 Patient charts were reviewed and the following data was 
collected: age, race, smoking status, and presence of diabetes 
mellitus, CHF, CVA, and coronary artery disease (CAD).  Height and 
weight data, which allowed calculation of the BMI (Body Mass Index), 
was also collected.  Patients were classified into five groups according 
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the WHO classification [57-58]: Normal (BMI < 25.0), overweight (BMI 
25.0 to 29.9), and obesity (BMI ≥ 30) was subdivided into grade 1 
(BMI 30 to 34.9), grade 2 (BMI 35 to 39.9), and grade 3 (morbid, BMI 
≥ 40) [57].  Primary outcome for this study was the prevalence of OSA 
among this group of patients with VTE.  OSA was defined as an apnea-
hypopnea index (AHI) of ≥ 5 by overnight polysomnography or the 
presence of OSA in the patient’s medical history confirmed by a sleep 
study in an outside laboratory not available for our review.   Please see 
the results section for demographics of this study population (may also 
see Table 1). 
 
Statistical analysis  
 
Data were entered into a database (Microsoft Excel, Microsoft 
Corporation, Redmond, WA, 2007).  The cohort was then divided into 
groups according to presence or absence of OSA.  The two groups 
(OSA and No-OSA) were then compared.  Continuous data were 
expressed as means or medians according to normality testing using 
Kolmogorov-Smirnov tests and compared using the student T or the 
Mann-Whitney tests whichever applicable.  Categorical variables were 
expressed as percentages and compared using the chi-square or Fisher 
exact tests.  For statistical analysis, parametric or non-parametric 
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tests were used according to normality testing.  Furthermore, the 
prevalence of OSA was estimated according to classes of BMI.  
Statistical significance was defined as p <0.05 and all tests were two-
sided. 
 
Receiver operating characteristics (ROC) analysis was used to 
evaluate the performance of BMI in the prediction of OSA among 
patients with VTE.  Area under the curve with 95% confidence interval 
was estimated.  According to the curve we defined the cut-off value 
with best combination of sensitivity and specificity.   
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Results 
 
From August 1999 - April 2009, 1239 patients were found to 
have the included ICD-9 codes and were screened. Of those 1239 
patients, 840 patients were included in the study and 399 were 
excluded.  Most patients were excluded due to the inability to confirm 
VTE or BMI.  Figure 1 illustrates the consort diagram for study 
inclusion and exclusion.  Of the 840 patients with VTE, 130 were also 
diagnosed with OSA yielding a prevalence of 15.5% of OSA in the 
cohort.    
 
Table 1 (and Figure 2) illustrates the demographics and Table 2 
(and Figure 3 and 4) illustrates the co-existing medical conditions and 
outcomes of the patients included in the study.  453 (53.9%) patients 
were females and the median age was 55 (18-94).  Figure 3 illustrates 
the breakdown of VTE by the presence or absence of OSA.  Of the 840 
patients, 619 (73.8%) had DVT with 524 (73.9%) in the No-OSA 
group and 95 (73.1%) in the OSA group (p = 0.843).  530 (63.3%) of 
the patients had PE with 439 (61.9%) in the No-OSA and 91 (71.7%) 
in the OSA group (p = 0.047).  309 (36.8%) had both DVT and PE 
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with 253 (35.6%) in the No-OSA group and 56 (43.1%) in the OSA 
group (p=0.106).   
 
When comparing the two groups (OSA, No-OSA), there was no 
difference in age, race, gender or rates of CVA events (p > 0.05 - see 
Table 1, 2 and Figure 2 for details).  Compared to the control group 
(No-OSA), those who had OSA were more obese (83.8% versus 
43.8%) and had higher rates of diabetes, CAD, and CHF (p-values: 
<0.0001, <0.0001, 0.028, and <0.0001, respectively - see Table 2 or 
Figure 4 for details).   
 
As obesity was associated with OSA in this study, OSA 
prevalence was divided into obesity categories.  Figure 5 illustrates 
prevalence of OSA according to grade 1 (BMI 30-34.9), 2 (BMI 35-
39.9), and 3 (BMI >40) BMI categories. There was a clear trend of 
increasing prevalence of OSA based on BMI.  Both the normal and 
overweight groups had rates comparable to the general population but 
the three obese (grade 1, grade 2 and grade 3 - morbid) had much 
higher prevalence with rates reaching 50% in the morbidly obese 
(grade 3) group.  
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In order to provide numbers to assist in clinical decision making, 
ROC analysis was preformed.  Figure 6 depicts the ROC curve 
according to BMI.  The analysis had good performance with area under 
the curve (AUC) of 0.797 [95% confidence intervals (0.753-0.840), p 
<0.0001]. The best cut-off value for diagnosis of OSA in patients with 
VTE was a BMI of 34.  This yielded a sensitivity of 78% and specificity 
of 75%.  If a primary care provider has a patient present with a new 
VTE, the ROC analysis suggests a BMI of 34 or greater as the best cut-
off to consider a polysomnogram. 
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Discussion 
 
In this population of patients with confirmed VTE, the prevalence 
of OSA (15.5%) is higher than the general population (2-10%) [3].  
Our data also suggests that patients with prior diagnoses of OSA and 
VTE are more likely to be obese with higher rates of CAD, CHF and 
diabetes (Figure 4).  Remarkably, there was no difference in age 
between the two groups although age is clearly listed as  risk factor for 
VTE in the literature.  Interestingly, the OSA group had higher 
prevalence of PE (71.7% vs. 61.9%; p=0.047) but similar rates of DVT 
(see Figure 3).  This latter finding may, in part, explain the higher 
overall cardiovascular mortality in OSA patients noted by other studies 
[5].  Although OSA has been clearly linked to arterial thrombosis, this 
study suggests a link between OSA and the venous thrombotic 
disorders.  However, obesity could be an underlying association 
between OSA and VTE. 
 
Our findings are consistent with previous studies that have also 
noted a relationship between OSA and VTE.  Ambrosetti  et al. have 
shown through a limited sample size study (N=89) that OSA patients 
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appear to be at increased risk of VTE [8].  Of 89 patients with OSA, 2 
developed proximal DVTs and one of those patients developed PE over 
a 3 year follow-up.  Another study by Arnulf et al. showed that in 
patients (N=68) admitted to the hospital with a VTEs, 82.4% (56/68) 
had an AHI ≥ 5 and 63% (43/68) had an AHI > 15 [9]. 
 
Obesity appears to be a common factor between OSA and VTE.  
In our OSA group, 83.8% of the patients were obese with a median 
BMI of 40.69 (versus 43.8% and a BMI of 29.09 in the No-OSA 
cohort), although the causal relationship is unclear.  Obesity has been 
shown to effect hemostasis by many of the same mechanisms as OSA.  
As summarized by Stein and Goldman, obesity has been shown to 
effect fibrinolysis, plasminogen activator inhibitor-1 levels and platelet 
aggregability [59].   
 
In our study we found a clear trend of higher prevalence rates of 
OSA with increasing BMI (see Figure 5). The morbidly obese group 
(BMI ≥ 40) had a prevalence rate of about 50% indicating that one-
half of the patients in this group had OSA.  ROC analysis showed that 
a BMI of 34 was the best cut-off value.  Our data suggests that sleep 
evaluation may be necessary in those patients with prior VTE and 
obesity grades 1, 2 or 3 as these three groups had much higher 
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prevalence of OSA.  In the other 2 groups (normal and overweight) 
OSA was comparable to general population, thus sleep evaluation 
might be based on other suggestive signs and symptoms rather than 
BMI.  
 
Our study has limitations.  The retrospective design limits our 
conclusions with the inherent weakness included in this design.  ICD-9 
coding was initially used to identify patients although complete chart 
reviews were performed to confirm included data.  We found that 
many patients that were labeled by ICD-9 code as VTE, did not 
actually have the disease. Although unexpected, we consider this as a 
strength for our study as it required data to be confirmed for every 
patient.  Another limitation is that we could not consistently ascertain 
whether OSA preceded VTE or vice versa, and thus, we expressed the 
percentage of OSA patients as a prevalence rather than incidence.  In 
addition, we did not have access to all the sleep studies as many of 
them were performed in outside laboratories.  In these instances, we 
chose not classify the patient as sleep apnea unless we found objective 
evidence in the chart that the patient carried this disorder.  We 
excluded patients that were described as high risk or potentially 
having OSA, without evidence of sleep study.  Many patients may have 
had OSA without a clear medical record or proper testing and 
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diagnosis; these were not included in our study.  These uncertainties 
may have led to underestimation of the prevalence of OSA in this 
cohort. 
 
 Additional study limitations include the inability to have a true 
control group due to study design.  Examining a cohort of patients with 
similar BMIs without obstructive sleep apnea would allow additional 
conclusions and analysis of data.  Further studies would benefit from 
having an established control group of patients with comparable co-
morbidities without OSA. 
 
Our study also has many strengths.  This is the largest cohort in 
the literature that investigates the relationship between OSA and VTE.  
Further, the previous two other reports had 157 patients combined [8-
9].  We confirmed the diagnoses of VTE and OSA and also studied 
baseline characteristics to discern if the relationship is independent or 
confounded by obesity, a common factor between these two disorders. 
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Conclusion 
 
Patients with VTE do have a higher prevalence of OSA (15.5%) 
as compared to the general population.  CAD, CHF, and diabetes also 
appear to be more prevalent in patients with both VTE and OSA as 
compared to patients with VTE alone.  Obesity continues to be one of 
the confounding variables and obesity also increases the risk of VTE, 
OSA, and many other medical conditions.  Of particular interest, in a 
cohort of patients with VTE, we found similar prevalence of DVT but 
increased prevalence of PE in patients with OSA.  Although OSA has 
been clearly linked to arterial thrombosis, this study suggests a link 
between OSA and VTE.  Further studies are necessary to clarify the 
possible association between these disorders. 
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Further Studies 
 
Due to the high prevalence of obesity and OSA, further studies 
of the development of VTE in OSA patients would be helpful to clarify 
the causal relationship between these diseases.  Current plans include 
a retrospective study looking at patients diagnosed with OSA and two 
prospective studies.  The studies have been registered with 
clinicaltrials.gov.  In the retrospective study, comparable methods will 
be used to examine the prevalence of VTE in patients diagnosed with 
OSA.  In this study, attempts will be made to establish a time-line of 
the diagnoses of VTE and OSA.  Establishing a time-line between the 
onset of OSA and development of VTEs may be helpful in elucidating 
the relationship between the two diseases. 
 
In the first prospective study, inclusion criteria will be patients 
greater than 18 years of age that have current or previous VTEs.  
Patients will be located through the Thromboembolic Clinic at the 
University of Missouri and/or through admission at the University of 
Missouri Hospital.  This study was approved through the University IRB 
under waiver of documentation of consent.  After verbal consent is 
obtained, patients will be given a sleep questionnaire including the 
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Epworth Sleepiness Scale [60].  The Epworth Sleepiness Scale is a 
measure of the degree of patient sleepiness in imaginary situations.  
The sleep questionnaire will also include information on demographics, 
height, weight, sleep hygiene, and medical co-morbidities.  
Furthermore, if the patient is found to score high on the Epworth 
Sleepiness Scale (>8), they will be encouraged to discuss the prospect 
of a sleep study with their primary care physician.  These patients will 
then be followed for a year and monitored for the diagnosis of OSA.  
Currently 25 patients have been enrolled in this study. 
 
In the second prospective study, inclusion criteria will be 
patients greater than 18 years of age that are admitted to the 
University or Columbia-Regional sleep labs.  This study was also 
approved by the University of Missouri IRB under waiver of 
documentation of consent.  After verbal consent is obtained, these 
patients will be offered a questionnaire to evaluate for a past medical 
history of VTE.  Sleep study results will be viewed after the sleep study 
for the diagnosis of OSA.  Also, a thorough review of the patients 
medical record will be performed for demographics and medical co-
morbidities.  These patients will then be followed for the next year to 
monitor for the development of VTE by the means of a phone call to 
the patient and medical records.  This study will allow the estimation 
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of incidence of symptomatic VTE (both PE and DVT) in patients with 
OSA.  Currently approximately 100 patients have been enrolled in this 
section of the study. 
  
The second study with also have the benefit of a control group.  
Patients that undergo sleep studies and do not qualify as OSA patients 
will provide a proper control group.  This will allow proper comparisons 
and proper controls for obesity and other confounders.  This current 
study was unable to benefit from a true control group as there was no 
set criteria for what a "control" patient would be.  The ICD-9 search 
included patients coded for VTE and to analyze data for the patients 
that do not have a coding for VTE (all the other patients in the 
University health system) would be unfeasible.  Set criteria for control 
patients would need to have been set from the beginning and set 
criteria for control patients would have their own limitations by 
inherent design. 
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Clinical Implications 
 
This is the largest study to examine the relationship between 
VTE and OSA.  In this study, we found that patients diagnosed with 
VTE have a higher prevalence of OSA than the general population.  
This suggests that patients who are found to have VTE should be 
considered for evaluation for OSA by overnight polysomnogram.  
However, further studies are necessary to confirm these findings.  
Furthermore, after breaking down the prevalence of OSA by BMI, we 
found that above a BMI of 34 in patients with VTE confers a sensitivity 
of 78% and specificity of 75% for OSA.  This study does have the 
confounder of obesity, so this limits the clinical implications. 
 
In future studies, we hope to further investigate the link 
between OSA and VTE.  If our hypothesis is correct, patients that are 
found to have VTE should be investigated for OSA and patients found 
to have OSA should be considered a higher risk for thrombosis.  
Currently OSA has been linked to multiple cardiovascular diseases, but 
not specifically to VTE.  If OSA does induce a hypercoagulable state, it 
would be of interest to study the treatment of continuous positive 
airway pressure and its effect on this state.  Also, there potentially 
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could be implications on the length and/or initiation of anticoagulation 
in patients with OSA and/or VTE. 
 
Healthcare workers should be aware of the association between 
OSA and VTE particularly since both of these diseases by themselves 
are associated with high morbidity and mortality.  
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Tables, Figures, and Legends 
   
 
 
Titles 
 
Figure 1.  Consort Diagram for Study Population. 
 
Table 1.  Demographics of the study patients and those with or 
without obstructive sleep apnea. 
 
Table 2.  Co-existing medical conditions and outcomes for the study 
population.   
 
Figure 2.  Baseline demographics of the study population. 
 
Figure 3.  VTE outcomes separated by study groups (OSA vs No-
OSA). 
 
Figure 4.  Co-morbid conditions in the study population separated by 
the presence or absence of OSA. 
 
Figure 5.  Prevalence of OSA among patients with VTE according to 
BMI categories. 
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Figure 6.  Receiver operating characteristics (ROC) curve for BMI 
predicting the status of OSA. 
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Legends 
 
 
Figure 1.   
1239 patients with ICD-9 coding for venous thromboembolic events 
(VTE) were enrolled in the study.  840 were included and 399 were 
excluded for various reasons.  Of the 840, 130 were also diagnosed 
with obstructive sleep apnea (OSA) for a prevalence of 15.5%.   
 
Table 1.   
Demographics for the study population.  There was no difference in 
age, race or sex.  Patients with higher body-mass indices (BMI) had a 
higher prevalence of OSA.  
 
Table 2.   
Co-existing medical conditions and outcomes for the study population.  
Venous thromboembolic event (VTE) patients that were found to have 
obstructive sleep apnea (OSA) had a higher prevalence of obesity, 
coronary artery disease (CAD), congestive heart failure (CHF), and 
type 2 diabetes (DM 2).  There was a trend towards a higher 
prevalence of strokes and smoking.  The patients with OSA also had 
more pulmonary embolisms (PE). 
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Figure 2.  
No difference was found in gender, race or age between the OSA and 
No-OSA groups. 
 
Figure 3. 
When comparing the study population separated by the presence or 
absence of OSA, no difference was found between prevalence of DVT.  
The OSA group has a significantly higher prevalence of PE and a trend 
towards higher prevalence of the combination of DVT and PE. 
 
Figure 4. 
When comparing the study population separated by the presence or 
absence of OSA, there were significantly more OSA patients with type 
2 diabetes (DM 2), congestive heart failure (CHF), and coronary artery 
disease (CAD).  Also, there was a trend towards increased stroke and 
patients that were smokers in the OSA subset of patients. 
 
Figure 5.   
OSA prevalence increased with higher BMI (body-mass index) in 
patients with VTE.  The morbidly obese group (BMI ≥ 40) had an 
obstructive sleep apnea (OSA) prevalence rate of about 50%. 
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Figure 6.   
Best Cut-Off value was found to be a BMI of 34 with a sensitivity of 
78% and specificity of 75%.  In patients with venous 
thromboembolsim (VTE) and a body-mass index (BMI) greater than 
34, the sensitivity is 78% and specificity 75% for obstructive sleep 
apnea (OSA). 
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Table 1. 
 
 
Groups 
 
No-OSA 
710 (84.5%) 
OSA 
130 (15.5%) 
Total 
840 (100%) 
 
P-values 
Female Gender - 
n (%) 
390 (54.9) 63 (48.5) 453 (53.9) 0.174 
Age - 
median (range) 
55 (18-94) 53.5 (29-84) 
55 (18-94) 0.969 
BMI - 
median (range) 
29.09 
(15.40-119.6) 
40.69 
(20.90-169.75) 31.49 
(15.4-169.75) 
<0.0001 
BMI– Normal 
n (%) 
194 (27.3) 8 (6.2) 
202 (24) <0.0001 
BMI– Overweight 
n (%) 
205 (28.9) 13 (10) 
218 (26) <0.0001 
BMI– Obesity 
n (%) 
311 (43.8) 109 (83.8) 
420 (50) <0.0001 
Grade 1 140 (19.7) 15 (11.5) 
155 (18.5) <0.0001 
Grade 2 93 (13.1) 23 (17.7) 
116 (13.8) <0.0001 
Grade 3 
(morbid) 
78 (11) 71 (54.6) 
149 (17.7) <0.0001 
Race   
 0.67 
White n (%) 608 (86.4) 108 (85) 
716 (86.2)  
Black n (%) 86 (12.2) 18 (14.2) 
104 (12.5)  
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Table 2. 
 
 
Groups 
 
No-OSA 
710 (84.5%) 
OSA 
130 (15.5%) 
Total 
840 (100%) 
 
P-values 
DVT n (%) 524 (73.9) 95 (73.1) 
619 (73.8) 0.843 
PE n (%) 439 (61.9) 91 (71.7) 
530 (63.3) 0.047 
DVT and PE n (%) 253(35.6) 56(43.1) 
309(36.8) 0.106 
Smoking n (%) 319 (44.9) 70 (53.8) 
389 (46.3) 0.061 
Diabetes   
 <0.0001 
Type 1 n (%) 43 (6.1) 7 (5.4) 
50 (6)  
Type 2 n (%) 107 (15.1) 44 (33.8) 
151 (18.0)  
CHF n (%) 60 (8.5) 26 (20) 
86 (10.2) <0.0001 
STROKE n (%) 71 (10) 19 (14.6) 
90 (10.7) 0.118 
CAD n (%) 109 (15.4) 32 (24.6) 
141 (16.8) 0.028 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
 
 
